Transdermal Drug Delivery System: A Novel Alternative for Drug Delivery

Abstract

Orally administered pharmaceuticals now account for 74% of all prescriptions, however studies have shown that oral medications are often less effective due to first pass metabolism and not stable drug blood level etc. Transdermal drug delivery system (TDDS) was developed to enhance such qualities. Every 2.2 years, the FDA grants approval for a new transdermal medication delivery system, fueling a multibillion dollar industry. An extensive evaluation of the technology, business, and products has been warranted since the FDA initially authorized the first transdermal medicine patch around 40 years ago. Transdermal medication delivery systems on demand are made possible by patches, a special kind of patch. The transdermal medication delivery system's adhesive plays a key role in the product's safety, effectiveness, and quality. Compared to more traditional delivery modalities, such as oral or invasive injection, topical therapy provides several benefits. Limiting hepatic first-pass metabolism, improving therapeutic efficacy, and maintaining a constant plasma level are all benefits of transdermal drug administration. Types of transdermal patches, production techniques, mechanism of action, kinetics, clinical concerns, and their physicochemical methods of assessment are all covered in this article.